4d Pharma posts more "positive" results from Blautix probe

(Alliance News) - 4d Pharma PLC on Monday reported additional data from a probe of its Blautix ...

Alliance News 24 May, 2021 | 9:20AM
Email Form Facebook Twitter LinkedIn RSS

(Alliance News) - 4d Pharma PLC on Monday reported additional data from a probe of its Blautix treatment, which has been found to improve symptoms in sufferers of irritable bowel syndrome.

4d Pharma posted "encouraging" topline results from a phase II BHT-II-002 trial back in October.

A deeper dive into the data has found Blautix offered a "strong and statistically significant activity on the key symptom of bowel habit".

"4D pharma has been able to review the data in more detail. We have also discussed the results with internationally renowned key opinion leaders and patient groups. We are encouraged by the positive outcomes of this additional analysis, and we strongly believe that this signal finding study supports the continued development of Blautix as a novel treatment for IBS," Chief Scientific Officer Alex Stevenson said.

There were "consistent improvements in bowel habit" in patients that used Blautix.

Shares in the company were 1.3% higher at 98.30 pence each in London on Monday morning.

By Eric Cunha; ericcunha@alliancenews.com

Copyright 2021 Alliance News Limited. All Rights Reserved.

Email Form Facebook Twitter LinkedIn RSS

Securities Mentioned in Article

Security Name Price Change (%) Morningstar
4d pharma PLC 104.80 GBX 4.80 -

About Author

Alliance News

Alliance News provides Morningstar with continuously updating coverage of news affecting listed companies.

Audience Confirmation

By clicking 'accept' I acknowledge that this website uses cookies and other technologies to tailor my experience and understand how I and other visitors use our site. See 'Cookie Consent' for more detail.

  • Other Morningstar Websites
© Copyright 2021 Morningstar, Inc. All rights reserved.

Terms of Use        Privacy Policy        Cookies       Modern Slavery Statement